Latest news with #EisaiCo
Business Insider
01-06-2025
- Business
- Business Insider
Morgan Stanley Sticks to Their Hold Rating for Eisai Co (ESALF)
In a report released on May 29, Shinichiro Muraoka from Morgan Stanley maintained a Hold rating on Eisai Co (ESALF – Research Report), with a price target of Yen4,100.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Muraoka covers the Healthcare sector, focusing on stocks such as Astellas Pharma, Daiichi Sankyo Company, and Eisai Co. According to TipRanks, Muraoka has an average return of -3.9% and a 33.33% success rate on recommended stocks. In addition to Morgan Stanley, Eisai Co also received a Hold from Jefferies's Stephen Barker in a report issued yesterday. However, on May 15, Bernstein maintained a Buy rating on Eisai Co (Other OTC: ESALF).
Business Insider
01-06-2025
- Business
- Business Insider
Eisai Co (ESALF) Gets a Hold from Jefferies
Jefferies analyst Stephen Barker maintained a Hold rating on Eisai Co (ESALF – Research Report) yesterday and set a price target of Yen4,200.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Barker is a 2-star analyst with an average return of 1.4% and a 44.12% success rate. Barker covers the Healthcare sector, focusing on stocks such as Sumitomo Dainippon Pharma Co, Astellas Pharma, and Asahi Intecc Co. Currently, the analyst consensus on Eisai Co is a Moderate Buy with an average price target of $35.06.
Bloomberg
31-01-2025
- Health
- Bloomberg
EU to Weigh New Safety Data on Biogen, Eisai Alzheimer's Drug
Business European Union regulators will review new information relating to the safety of Eisai Co. 's and Biogen Inc. 's medicine for Alzheimer's disease, providing a response after a meeting next month. The drug, Leqembi, can slow the progression of Alzheimer's, the mind-robbing disease that afflicts millions. But it has been linked to brain swelling and bleeding, posing a challenge to regulators who must weigh patients' lack of treatment options against the risk of side effects.
